Quick Answer
Genprex, Inc. reported Total Revenue of $0.00 for fiscal year 2024.
Genprex, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$16.23M +23.1% |
-$21.11M +31.6% |
-$30.86M -30.0% |
-$23.74M -14.9% |
-$20.66M -15.2% |
-$17.94M -68.4% |
| Total Assets | $10.16M +146.3% |
$4.12M -61.3% |
$10.67M -72.9% |
$39.41M -8.1% |
$42.86M +36.6% |
$31.37M +787.5% |
| Cash and Equivalents | $7.83M +388.9% |
$1.60M -76.2% |
$6.74M -67.8% |
$20.95M | — | — |
| Stockholders Equity | $7.96M +391.4% |
$1.62M -78.2% |
$7.42M -80.0% |
$37.02M -10.3% |
$41.28M +33.5% |
$30.92M +922.5% |
| R&D Expense | $9.43M -10.5% |
$10.54M -40.2% |
$17.62M +53.1% |
$11.51M +28.3% |
$8.97M +22.8% |
$7.30M +271.3% |
| Operating Income | -$15.52M +26.7% |
-$21.17M +31.8% |
-$31.06M -30.3% |
-$23.83M -15.3% |
-$20.67M -15.1% |
-$17.96M -68.1% |
| Shares Outstanding | 3.29M +1415.2% |
217,234 -85.4% |
1.49M +23.5% |
1.20M -97.5% |
47.87M +11.0% |
43.12M +123.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2022 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$3.80M | +12.0% | +18.7% |
| Total Assets | September 30, 2025 | $3.56M | -8.8% | -6.9% |
| Cash and Equivalents | September 30, 2025 | $1.10M | -25.9% | -18.1% |
| Stockholders Equity | September 30, 2025 | $767.8K | -53.9% | -44.8% |
| R&D Expense | September 30, 2025 | $2.19M | -20.4% | -12.3% |
| Operating Income | September 30, 2025 | -$3.35M | +22.6% | +28.5% |
| Shares Outstanding | September 30, 2025 | 1.00M | -81.7% | -97.0% |
- Genprex, Inc. reported Total Revenue of $0.00 for fiscal year 2024.
- Genprex, Inc. reported Net Income of -$16.23 million for fiscal year 2025.
- Genprex, Inc. showed an increase of +23.1% in Net Income compared to the prior fiscal year.
- Genprex, Inc. reported Total Assets of $10.16 million for fiscal year 2025.
- Genprex, Inc. showed an increase of +146.3% in Total Assets compared to the prior fiscal year.
- Genprex, Inc. reported Cash and Equivalents of $7.83 million for fiscal year 2025.
- Genprex, Inc. showed an increase of +388.9% in Cash and Equivalents compared to the prior fiscal year.
- Genprex, Inc. reported Stockholders Equity of $7.96 million for fiscal year 2025.
- Genprex, Inc. showed an increase of +391.4% in Stockholders Equity compared to the prior fiscal year.
- Genprex, Inc. reported R&D Expense of $9.43 million for fiscal year 2025.
- Genprex, Inc. showed a decrease of -10.5% in R&D Expense compared to the prior fiscal year.
- Genprex, Inc. reported Operating Income of -$15.52 million for fiscal year 2025.
- Genprex, Inc. showed an increase of +26.7% in Operating Income compared to the prior fiscal year.
- Genprex, Inc. reported Shares Outstanding of 3.29 million shares for fiscal year 2025.
- Genprex, Inc. showed an increase of +1415.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: